My Cart

Cathepsin B

Cathepsin B Overview

English NameCathepsin BApproved Drugs0
Drugs in Clinical Trials2Target SynonymEC 3.4.22,EC:3.4.22.1,RECEUP,Cathepsin B,Amyloid Precursor Protein Secretase,Epididymis Secretory Sperm Binding Protein,Cathepsin B1,Cysteine Protease,EC 3.4.22.1,CPSB,APPS,APP secretase,CTSB
Highest Development StagePhase 2 Clinical
English NameCathepsin B
Target SynonymEC 3.4.22,EC:3.4.22.1,RECEUP,Cathepsin B,Amyloid Precursor Protein Secretase,Epididymis Secretory Sperm Binding Protein,Cathepsin B1,Cysteine Protease,EC 3.4.22.1,CPSB,APPS,APP secretase,CTSB
Approved Drugs0
Drugs in Clinical Trials2
Highest Development StagePhase 2 Clinical

Cathepsin B Product List

  • Product Category

    Protein (4)

  • Product Status

    Launched (4)

  • Species

    Human (3)Mouse (1)

  • Tag

    His Tag (3)Tag Free (1)

  • Conjugate

    Unconjugated (4)

Cathepsin B Background

Cathepsin B (CTSB) is also known as APP secretase (APPS) and CPSB, is an enzymatic protein belonging to the peptidase C1 family. Cathepsin B / CTSB is synthesized as a preproenzyme. Following removal of the signal peptide, the inactive proenzyme undergoes further modifications including removal of the pro region to result in the active enzyme. The catalytic activity of Cathepsin B / APPS contains: Hydrolysis of proteins with broad specificity for peptide bonds; Preferentially cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates (thus differing from cathepsin L); In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. As a thiol protease, cathepsin B / CPSB is believed to participate in intracellular degradation and turnover of proteins and has also been implicated in tumor invasion and metastasis. Overexpression of cathepsin B has been associated with esophageal adenocarcinoma and other tumors.

Cathepsin B Synonyms

CTSB,CPSB,APPS

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
OsugacestatAL-101(BMS); BMS-906024; BM-0018Phase 2 ClinicalBristol-Myers Squibb Company, Glaxosmithkline PlcNeoplasms; Triple Negative Breast Neoplasms; Carcinoma, Adenoid Cystic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Details
cysteine protease inhibitor (Boehringer Ingelheim)Phase 1 ClinicalBoehringer Ingelheim International GmbhRespiratory Tract Diseases
Details

Product Reviews

  • W***I2025-11-07
    0People Like
    We purchased this protein for binding activity experiments. For parallel replicates, the CV value between them can be maintained at 15%, the results between multiple experiments are stable, and the data accuracy and precision meet the requirements.
  • M***i2025-04-05
    0People Like
    Product was purchased to utilize in a val-cit cleavage assay for a protein-drug conjugate. The protein did not take long to arrive and the assay instructions were clear to follow and promptly given upon request. I was readily able to utilize the protein for the desired cleavage assay using the provided protocol and it worked great. I am satisified with the quality and the price of this reagent.
  • Overview
  • Product List
  • Product Reviews
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland